DiaMedica Therapeutics Inc. (DMAC) financial statements and ratios from SEC XBRL: revenue $1.67M (TTM), net margin -1963.2%, revenue growth -27.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.67M |
| Net Margin | -1963.2% |
| Revenue Growth (YoY) | -27.5% |
| EPS Growth (YoY) | 16.7% |
| FCF Growth (YoY) | 31.7% |
| Price / Book | 9.16 |
| Price / Sales | 207.36 |
| FCF Yield | -16.2% |
| Altman Z-Score | 35.33 (safe) |
| Sector P/E (Healthcare) | 21.7 |
DMAC overview · DMAC earnings · DMAC KPIs · DMAC investor relations · DMAC ownership · DMAC peers · DMAC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.